PCSK6

Across TCGA pan-cancer cohorts, PCSK6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCSK6 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCSK6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCSK6 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and LSCC are the cancer types where PCSK6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.184	0.854	.006	21	view →
CCRCC	OS	Tertile	All	0.826	1.000	.025	2	view →
LSCC	DFS	Tertile	III,IV	0.665	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCSK6–LUAD (DFS)

Open the LUAD breakdown →